Drug intelligence / Profile preview

SIG-018

Development stage: Preclinical
Lead developer: Eli Lilly

Overview

SIG-018 is a preclinical investigational therapy from Sigilon Therapeutics being developed for mucopolysaccharidosis type II and related congenital and nervous system manifestations associated with iduronate-2-sulfatase deficiency. Based on the provided context, it is described as an iduronate-2-sulfatase modulator intended to address Hunter syndrome biology by acting on the IDS pathway, but no additional public details were provided on its exact molecular format, delivery platform, route of administration, or whether it is designed as direct enzyme replacement, gene-based therapy, or another modality.

Targets

IDS (Iduronate-2-sulfatase)

Beyond the preview

Go deeper on SIG-018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIG-018.

Explore the full profile